RPG Life Sciences Subsidiary RPG Active Pharma Approves Amalgamation of Actis Generics

Market snapshot: RPG Active Pharma Limited, a wholly owned subsidiary of RPG Life Sciences Limited, has approved a scheme of amalgamation to merge its wholly owned subsidiary, Actis Generics Private Limited, with itself. The corporate restructuring, approved by the board on September 25, 2026, aims to consolidate assets, streamline operations, and eliminate duplicate administrative costs.

Data Snapshot

• Actis Generics reported standalone revenue from operations of ₹45.96 crore for the financial year ended March 31, 2026.
• Actis Generics recorded a standalone net worth of ₹34.60 crore as of March 31, 2026.
• RPG Active Pharma recorded a standalone net worth of ₹34.75 crore with zero operational revenue as of March 31, 2026.
• RPG Life Sciences reported Q1 FY27 standalone revenue from operations of ₹195.7 crore, up 15.8% year-on-year from ₹168.9 crore in Q1 FY26.

What's Changed

• RPG Life Sciences' standalone quarterly revenue increased 15.8% year-on-year to ₹195.7 crore in Q1 FY27 from ₹168.9 crore in Q1 FY26.
• Standalone EBITDA grew 17.9% year-on-year to ₹48.0 crore in Q1 FY27 from ₹40.7 crore in Q1 FY26, expanding the EBITDA margin to 24.5%.

Key Takeaways

• RPG Active Pharma's board approved the amalgamation scheme of Actis Generics with itself on September 25, 2026.
• The restructuring is an internal consolidation; no cash outflow or new share issuance will occur as Actis is already a wholly owned subsidiary.
• The amalgamation consolidates key active pharmaceutical ingredients and intermediate resources to reduce compliance and operational costs.
• This follows RPG Active Pharma's completion of the full acquisition of Actis Generics on September 24, 2026.

SAHI Perspective

The amalgamation of Actis Generics with RPG Active Pharma represents a logical consolidation step for RPG Life Sciences. Rather than operating Actis Generics as a separate subsidiary under the newly formed RPG Active Pharma, merging the two simplifies the corporate structure. It eliminates redundant administrative layers, reduces duplicate operational costs, and establishes a single consolidated entity for RPG's API operations. Backed by private equity funding and a buy-and-build strategy, this integration strengthens RPG's position in the niche, high-value API market.

Market Implications

Simplifying the group's corporate structure is a positive operational signal. By reducing compliance overheads and consolidating financial balances, the merged RPG Active Pharma is positioned to achieve a stronger net worth, potentially facilitating better terms with financial institutions and suppliers. This internal consolidation, paired with recent capacity expansions, demonstrates executive execution on hiving off and scaling up the API vertical, which should be viewed constructively by long-term investors.

Trading Signals

Market Bias: Bullish

RPG Life Sciences is rapidly organizing its API business for scale and efficiency. The amalgamation of Actis Generics eliminates administrative duplicity, enhancing operational leverage. Backed by strong Q1 FY27 results where revenue grew 15.8% to ₹195.7 crore and EBITDA grew 17.9% to ₹48.0 crore, the operational consolidation is expected to support margin expansion.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients (APIs)

Trigger Factors:

• National Company Law Tribunal (NCLT) and shareholder approvals for the amalgamation.
• Realization of cost synergies in administrative and compliance expenses.
• Commercialization of new API products under the unified entity.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global and Indian API industries are undergoing significant structural changes, with players increasingly integrating backwards to secure supply chains and mitigate price volatility. RPG Life Sciences' restructuring—subsidiarizing its API business into RPG Active Pharma, securing PE investment, and acquiring focused assets like Actis Generics (Vizag-based backward-integrated intermediates) and Raghava Life Sciences—reflects this trend. Consolidating Actis into RPG Active Pharma simplifies the delivery of these synergetic benefits.

Key Risks to Watch

• Delays in receiving NCLT or shareholder approvals for the scheme of amalgamation.
• Potential integration friction in combining distinct corporate workflows and management teams.
• Regulatory compliance of manufacturing facilities under the newly merged entity.

Recent Developments

RPG Active Pharma completed the acquisition of Actis Generics on September 24, 2026. Separately, on September 16, 2026, RPG Active Pharma completed the acquisition of the API and intermediates business of Raghava Life Sciences for up to ₹135 crore, expanding its total capacity to approximately 505 KL.

Closing Insight

By merging Actis Generics into RPG Active Pharma, RPG Life Sciences is taking a structured step to optimize its operational architecture. This internal consolidation eliminates dual administrative expenses and establishes a clean, unified platform to drive its ambitious growth strategy in the active pharmaceutical ingredients sector.

High Performance Trading with SAHI.